Sjörgren's syndrome treated with bromhexine: a randomised clinical study

Area of Science:

• Ophthalmology
• Rheumatology
• Pharmacology

Background:

• Sjögren's syndrome is an autoimmune disorder with unsatisfactory existing treatments.
• Uncontrolled observations suggested bromhexine may improve symptoms.

Purpose of the Study:

• To evaluate the efficacy of bromhexine in treating Sjögren's syndrome.
• To determine if bromhexine has a dose-dependent effect on ocular and oral symptoms.

Main Methods:

• Two randomized, double-blind, placebo-controlled crossover trials were conducted.
• Twenty-nine patients with Sjögren's syndrome received bromhexine (24 mg/day and 48 mg/day) or placebo.
• Ocular dryness was assessed using the Schirmer test and tear break-up time; oral dryness was assessed by time to eat a dry biscuit.

Main Results:

• Higher bromhexine dosage (48 mg/day) significantly improved Schirmer test response and tear break-up time.
• Bromhexine demonstrated a dose-dependent effect on lacrimal gland function.
• No significant effect was observed on salivary gland function.

Conclusions:

• Bromhexine is a valuable therapeutic option for improving ocular symptoms in Sjögren's syndrome.
• The drug's efficacy appears dose-dependent, particularly for lacrimal secretion.
• Further research may explore bromhexine's role in managing Sjögren's syndrome.